Wednesday, April 11, 2012 7:03:16 AM
Leiden, The Netherlands, April 11, 2012. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that it has redeemed the fourth tranche of its €8.4 million convertible bond. A total of 22,051,282 shares were issued to the bondholders under the terms and conditions of the bond, serving as a pre-installment for the May 15, 2012 redemption and interest payment.
As announced in our press release on December 23, 2011, Pharming will redeem the bond on a month by month basis in six equal monthly tranches of €1.4 million and the interest payable, such that the bond will be redeemed in full on July 15, 2012. Pharming can decide at its discretion to redeem the bond and pay the interest due, by means of monthly equity tranches or cash payments.
As of today, the number of outstanding shares has increased from 561,503,681 to 583,554,963.
Recent PHARM News
- Pharming Group reports first quarter 2024 financial results and provides business update • GlobeNewswire Inc. • 05/08/2024 05:00:00 AM
- Pharming Group reports first quarter 2024 financial results and provides business update • GlobeNewswire Inc. • 05/08/2024 05:00:00 AM
- Pharming Group to report first quarter 2024 financial results on May 8 • GlobeNewswire Inc. • 04/24/2024 06:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/19/2024 04:43:36 PM
- Pharming Group announces the placement of €100 million convertible bonds due 2029 • GlobeNewswire Inc. • 04/18/2024 01:04:30 PM
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/18/2024 06:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming Group announces the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/04/2024 06:30:00 AM
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F • GlobeNewswire Inc. • 04/04/2024 05:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
- Pharming Group reports fourth quarter and full year 2023 financial results • GlobeNewswire Inc. • 03/14/2024 06:00:00 AM
- Pharming Group to report fourth quarter and full year 2023 financial results on March 14 • GlobeNewswire Inc. • 02/29/2024 07:00:00 AM
- Pharming Group to report fourth quarter and full year 2023 financial results on March 14 • GlobeNewswire Inc. • 02/29/2024 07:00:00 AM
- Pharming Group to participate in February investor conferences • GlobeNewswire Inc. • 02/08/2024 07:00:00 AM
- Pharming Group to participate in February investor conferences • GlobeNewswire Inc. • 02/08/2024 07:00:00 AM
- Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update • GlobeNewswire Inc. • 01/08/2024 06:00:00 AM
- Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update • GlobeNewswire Inc. • 01/08/2024 06:00:00 AM
- Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) • GlobeNewswire Inc. • 12/13/2023 06:00:00 AM
- Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib • GlobeNewswire Inc. • 11/21/2023 06:00:00 AM
- Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib • GlobeNewswire Inc. • 11/21/2023 06:00:00 AM
- Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval • GlobeNewswire Inc. • 11/10/2023 01:51:10 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM